Concepedia

Author

Ashok Gupta

Post Graduate Institute of Medical Education and Research

Also Known As

A Gupta, A K Gupta, ASHOK K. GUPTA, Ashish Gupta, Ashok Gupta, Ashok K Gupta, Ashok K. Gupta, Ashok KUMAR GUPTA, Ashok Kumar Gupta, AshokK Gupta

445

Publications

38.4K

Citations

49

H-Index

243

Concepts

All Affiliations

Post Graduate Institute of Medical Education and ResearchBristol-Myers Squibb (United States)Memorial Sloan Kettering Cancer CenterJohns Hopkins UniversitySidney Kimmel Comprehensive Cancer Center
AG

About

Ashok Gupta is an author at Post Graduate Institute of Medical Education and Research specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

31

87

4.4K

2

Health Sciences

15

18

701

3

Natural Sciences

7

7

435

4

Arts

1

1

17

5

Education

1

1

92

Ashok Gupta

×

151

Publications

37.3K

Citations

48

H-Index

YearCitations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer,

New England Journal of Medicine

2012

12.5K

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow,

New England Journal of Medicine

2012

7.9K

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan,

New England Journal of Medicine

2013

4.2K

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott,

Journal of Clinical Oncology

2014

2.2K

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi,

Journal of Clinical Oncology

2015

1.2K

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma,

Journal of Clinical Oncology

2016

839

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Peter H. O’Donnell, Christophe Massard,

JAMA Oncology

2017

839

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Scott Antonia, Sarah B. Goldberg, Ani Sarkis Balmanoukian,

The Lancet Oncology

2016

589

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles, Michiel S. van der Heijden, Daniel Castellano,

The Lancet Oncology

2020

485

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

David F. McDermott, Charles G. Drake, Mario Sznol,

Journal of Clinical Oncology

2015

438

Page 1